Veru (NASDAQ:VERU) announced its quarterly earnings results on Wednesday. The company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03), Morningstar.com reports. Veru had a negative return on equity of 17.63% and a negative net margin of 48.42%. The business had revenue of $2.59 million during the quarter, compared to analysts’ expectations of $5.30 million.
Veru (NASDAQ:VERU) remained flat at $$1.32 during trading on Thursday. The stock had a trading volume of 57,721 shares, compared to its average volume of 100,498. The stock has a market cap of $70.10, a PE ratio of -5.74 and a beta of 1.20. Veru has a 12 month low of $0.90 and a 12 month high of $3.00.
A number of brokerages have recently weighed in on VERU. HC Wainwright set a $5.00 price target on Veru and gave the company a “buy” rating in a research report on Thursday. Zacks Investment Research cut Veru from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 6th. Finally, ValuEngine cut Veru from a “hold” rating to a “sell” rating in a research report on Friday, November 17th.
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.